Announced details
Research and development related to human endometrial cells, implantation, cell therapy and regenerative medicine
The consolidated subsidiary ADRセラピューティクス株式会社 is conducting joint research with Nagoya University. No capital or personnel relationship is stated.
Located in Furo-cho, Chikusa-ku, Nagoya, Aichi Prefecture. The representative is Director-General Matsuo Seiichi (松尾清一). Established in 1939. The joint research will be conducted at the Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine. The principal investigator is Lecturer Yokoi Akira (横井暁), Department of Obstetrics and Gynecology, Nagoya University Hospital.
Furo-cho, Chikusa-ku, Nagoya, Aichi Prefecture (Nagoya University). The joint research will be conducted at the Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine.
Research and development expenses and other costs are already included in the current fiscal year's plan, and there is no change to the consolidated earnings forecast for the fiscal year ending March 2027.
The company does not address Contract Value / Offering price.
2 papers published in Fertility and Sterility (2010 and 2015)
| Item | Details |
|---|---|
| Names of Products / Services Covered | NeoCella (extracellular particle-containing liquid) |
| Counterparty | Nagoya University, National University Corporation Tokai National Higher Education and Research System |
| Counterparty overview | Located in Furo-cho, Chikusa-ku, Nagoya, Aichi Prefecture. The representative is Director-General Matsuo Seiichi (松尾清一). Established in 1939. The joint research will be conducted at the Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine. The principal investigator is Lecturer Yokoi Akira (横井暁), Department of Obstetrics and Gynecology, Nagoya University Hospital. |
| Relationship with the Company | The consolidated subsidiary ADRセラピューティクス株式会社 is conducting joint research with Nagoya University. No capital or personnel relationship is stated. |
| Contract Date | 25 September 2026 |
| Applicable area | Research and development related to human endometrial cells, implantation, cell therapy and regenerative medicine |
| Location | Furo-cho, Chikusa-ku, Nagoya, Aichi Prefecture (Nagoya University). The joint research will be conducted at the Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine. |
| Impact on Business Performance | Research and development expenses and other costs are already included in the current fiscal year's plan, and there is no change to the consolidated earnings forecast for the fiscal year ending March 2027. |
| Source | 2 papers published in Fertility and Sterility (2010 and 2015) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To analyze the functions and mechanism of action of NeoCella in human endometrial cells and examine its potential involvement in implantation.